news
Structural changes in SARS-CoV-2 Alpha and Beta variants revealed
A study has uncovered previously unknown properties of the Spike protein from the SARS-CoV-2 Alpha and Beta variants.
List view / Grid view
Protein
news
New technique developed for identifying therapeutic nanobodies
Researchers have used a new method for discovering nanobodies to identify potential therapeutics against SARS-CoV-2 infection.
whitepaper
Product hub: Octet® R series systems
Discover the new Octet R series systems, a comprehensive solution for screening and characterising molecular interactions such as protein-protein or protein-drug interactions.
whitepaper
Application note: Pushing the boundaries in pharmaceutical hit discovery with the novel waveRAPID® kinetic assay
We demonstrate the power of waveRAPID in streamlining the kinetic characterisation of large numbers of drug hit compounds, with results comparable to traditional surface plasmon resonance (SPR) and high reproducibility.
news
Dual antibodies effective against SARS-CoV-2 variants in animal study
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
article
Covalent fragment screening in cell-based phenotypic models of disease: a collaborative approach
The application of chemical perturbation approaches in phenotypic models is often used to identify protein targets for therapeutic discovery. Increasingly, small molecule fragments which covalently bind to their protein targets are being used to explore the druggable proteome and the resulting fragment‑protein interactions are characterised by chemoproteomic techniques. In this…
article
Better therapeutic antibodies by design
The binding specificity and high binding affinity of therapeutic antibodies makes them an ideal therapy for treating a wide range of human disorders. Advancements in antibody technologies have resulted in huge development success along with a boost in novel and improved treatment strategies. However, specific challenges and considerations are faced…
article
How to mix the best anti-SARS-CoV-2 cocktail
Neutralisation resistance generated by Spike (S) protein mutations in Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) poses a challenge to antibody therapies for COVID-19. Antibody cocktails targeting the S protein receptor binding domain (RBD) are one way to avoid viral neutralisation escape, however only certain antibody combinations are currently effective.…
article
Drug Target Review Antibodies ebook 2021
Within this ebook, find articles on antibodies to combat SARS-CoV-2 and an evaluation of the various therapeutic forms they can take.
news
Two COVID-19 vaccines show safety and strong immunity in infant model
Two groups of infant rhesus macaques received one of two potential COVID-19 vaccines, which were shown to elicit high levels of neutralising antibodies.
article
The other end of the antibody: Fc biology and immunotherapy
Dr Björn Frendeus outlines how the growing biology surrounding the inhibitory Fc receptor FcγRIIb defines a target for improving existing and future antibody treatments.
news
Researchers link SARS-CoV-2 PLpro to COVID-19 symptoms
Researchers have shown that the SARS-CoV-2 PLpro cuts human proteins so could potentially cause a range of COVID-19 symptoms.
news
Novel DNA vaccine for SARS-CoV-2 effective in rodent models
A new DNA vaccine encoding the SARS-CoV-2 Spike protein has shown promise at protecting mice and hamsters against COVID-19.
news
Drug target to halt progression of Parkinson’s disease identified
Scientists have shown that trapped LC3B protein in brain cells enables Parkinson's disease to spread, presenting a drug target.
news
Non-opioid based target identified to potentially treat chronic pain
Researchers have discovered that blocking TRPC5 activity treated chronic pain in mouse models of various conditions.
